Not yet recruiting
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
NCT07738887· Phase 2· The Lymphoma Academic Research Organisation· Source
Not yet recruiting
Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT07739459· Phase 2· The Lymphoma Academic Research Organisation· Source
Not yet recruiting
Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab
NCT07836283· Phase 3· University Hospital, Rouen· Source
Not yet recruiting
Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial
2026-525280-40-00· Phase 3· Fondation A De Rothschild· Source
Not yet recruiting
Impact of discontinuation of long-term macrolides in stable Non Cystic Fibrosis Bronchiectasis : a multicenter randomized controlled trial
2025-521493-33-00· Phase 3· Centre Hospitalier Intercommunal Creteil· Source
Not yet recruiting
Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2
2026-525759-96-00· Phase 4· Centre Hospitalier Universitaire De Toulouse· Source
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· Phase 3· AstraZeneca· Source
Recruiting
Withdrawal of Dupilumab in Severe Asthma
NCT06818019· Phase 4· University Hospital, Toulouse· Source
Recruiting
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
NCT06606730· Phase 3· UNICANCER· Source
Recruiting
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
NCT06918002· Phase 3· Intergroupe Francophone du Myelome· Source
Active, not recruiting
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895· Phase 3· Eli Lilly and Company· Source
Recruiting
Beta-blOckers discoNtinuation in patients presenting heart FaIlure with REcovered left ventricular ejection fraction
2023-508798-94-00· Phase 3· Assistance Publique Hopitaux De Paris· Source
Active, not recruiting
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360· Phase 3· Sanofi· Source
Recruiting
Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.
NCT06450314· Phase 2· UNICANCER· Source
Recruiting
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
NCT06641414· Phase 3· Ascentage Pharma Group Inc.· Source
Recruiting
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
NCT06078384· Phase 2· UNICANCER· Source
Recruiting
QUIDOSE. Randomized controlled trial testing the efficacy of hydroxychloroquine combined with low dose corticosteroid therapy in pulmonary sarcoidosis
NCT05247554· Phase 3· Assistance Publique Hopitaux De Paris· Source
Recruiting
Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis
NCT06368804· Phase 2· Centre Hospitalier Intercommunal Creteil· Source
Recruiting
FLUOCOL-1 : Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage
NCT05168839· Phase 4· Centre Hospitalier Regional Universitaire· Source
Not yet recruiting
Stopping Pneumonia Antibiotherapy Regimen Early
NCT06291012· Phase 4· University Hospital, Montpellier· Source
Active, not recruiting
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
NCT06268873· Phase 3· AstraZeneca· Source
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575· Phase 3· Pfizer· Source
Recruiting
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566· Phase 3· Ascentage Pharma Group Inc.· Source
Active, not recruiting
Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)
NCT06111586· Phase 2· Sanofi· Source
Active, not recruiting
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
NCT06097364· Phase 3· Regeneron Pharmaceuticals· Source
Active, not recruiting
Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)
NCT05768711· Phase 2· Groupe Francophone des Myelodysplasies· Source
Active, not recruiting
Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients
NCT06062537· Intergroupe Francophone du Myelome· Source
Recruiting
PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years
NCT05387954· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Contact: Philippe Niclot, MD
Active, not recruiting
A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML
NCT05199051· Phase 2· Centre Antoine Lacassagne· Source
Active, not recruiting
Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence
NCT05297617· Phase 2· Unicancer· Source
Recruiting
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
NCT05181735· Phase 1/2· Groupe Francophone des Myelodysplasies· Source
Active, not recruiting
MInimal Residual Disease Adapted Strategy
NCT04934475· Phase 3· Intergroupe Francophone du Myelome· Source
Active, not recruiting
Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis
NCT04870203· Phase 3· University Hospital, Bordeaux· Source
Recruiting
Short Treatment with Omalizumab for Severe Asthma
NCT04763447· Phase 4· Assistance Publique - Hôpitaux de Paris· Source
Active, not recruiting
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052· Phase 3· Incyte Corporation· Source
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
NCT04419649· Phase 2· Takeda· Source
Recruiting
Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
NCT03819101· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Active, not recruiting
Treatment Intensification With Temozolomide in Adults With a Glioblastoma
NCT03663725· Phase 3· Centre Oscar Lambret· Source
Recruiting
Chronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole
NCT03656081· Phase 3· Poitiers University Hospital· Source
Active, not recruiting
Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease
NCT03323476· Phase 3· Centre Hospitalier Departemental Vendee· Source
Completed
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
NCT03079011· Phase 3· UNICANCER· Source